LAM IPM(TM) Wound Gel Now Eligible For Medicare Reimbursement
LEWISTON, N.Y., March 27 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt
Stock Exchange: LAM), www.lampharm.com announced today that its breakthrough wound care product -- LAM
IPM(TM) Wound Gel -- will be eligible for the Medicare Homecare Reimbursement Plan once it receives FDA approval and is
recommended for use in patients who are being treated by wound care nurses under the cognizance of qualified wound care
professionals.
This highly successful, and fast expanding part of the Medicare system, provides for many patients to be treated at home, instead
of in a much more expensive hospital setting.
LAM IPM(TM) Wound Gel is classified as a hydrogel 510(k) device (FDA Assigned No. K020325) and, as such, home
treatment by specialized wound care nurses is currently paid for by the Medicare system, for this class of product, following
approval by the FDA. Monitoring of individual cases and progress reports are required by medical officials.
Because most patients suffering from severe skin ulcers, including diabetic ulcers, venous stasis ulcers and other severe ulcerated
skin conditions are over the age of 65, and thus are covered by Medicare, LAM Pharmaceutical, Corp. expects to be a major
beneficiary of this highly successful and enlightened Medicare program.
LAM IPM(TM) Wound Gel has enjoyed an 88% success rate in creating an effective moist environment to assist healing in
hard-to-heal ulcers in both animal and human studies while maintaining an extremely low incidence of side effects.
Alan Drizen, C.E.O. of LAM Pharmaceutical, Corp., said, ``We expect a decision from FDA on or about April 30, 2002,
regarding our 510(k) application. Upon receipt of a positive response, management believes that our forecast of US $27 million in
sales for 2003 and US $50 million in sales for 2004 can now be considered conservative. The suitability of our wound care
hydrogel (LAM IPM(TM) Wound Gel) for homecare, under present Medicare guidelines, makes it ideal for homecare use.``
Dazu die guten News vom 12.3.:
March 12, 2002 07:00
LAM Pharmaceutical Corp. Signs Marketing Agreement with RxCentric Inc. of New York City
Jump to first matched term
LEWISTON, N.Y., March 12 /PRNewswire-FirstCall/ -- LAM Pharmaceutical Corp. (OTC Bulletin Board: LAMP; Frankfurt Stock Exchange:
LAM), www.lampharm.com, is pleased to announce that it has signed a marketing agreement with RxCentric Inc. of New York City
in connection with its anticipated launch of its breakthrough product for the management of severe skin ulcers, LAM IPMTM Wound Gel.
RxCentric Inc., a leading provider of technology-enabled sales and marketing solutions for the pharmaceutical and biotech industry, has
captured the attention of the pharmaceutical and biotechnology and the medical community in the last few years by way of its novel and
innovative approach to marketing and product dissemination to medical professionals.
Using its database access to several hundred thousand of the busiest, office based, prescribing medical professionals, RxCentric Inc.
has developed 4-6 minute medical information messages which it uses to target the various types of health care professionals with
important information on new and existing products.
"Our agreement with LAM is a prime example of how we can customize online solutions quickly and at reasonable cost to help
pharmaceutical companies keep products top-of-mind with physicians," said Richard Findlay, President and Chief Executive Officer of
RxCentric. "The pharmaceutical industry rapidly is discovering that the Internet can improve and strengthen relationships with its key
customers -- physicians -- and extend the reach of sales programs. RxCentric`s services can support large and small products at all
stages of the product lifecycle: pre-launch, launch, mature, and late life-cycle."
RxCentric Inc. has designed successful programs for a significant number of major multi-national companies and has accepted LAM
Pharmaceutical, Corp. as a client because it strongly believes LAM IPM(TM) Wound Gel will become a leader in the ulcer sector of the
wound care market, which is the fastest growing segment of the pharmaceutical industry.
Alan Drizen, CEO of LAM Pharmaceutical, Corp. said, "This agreement comes at a perfect time for us. Our anticipated launch of our first,
and possibly most major product, is approximately only two months away. The national exposure that RxCentric Inc. will give LAM
IPM(TM) Wound Gel coupled with the medical presentation to the 15th Annual Symposium on Advanced Wound Care in Baltimore,
Maryland, coming at the end of April, will give many of our target group of health care professionals the information and samples they
need to learn about and evaluate the product in the most timely way."
Alan Drizen continued, "RxCentric executives and top management are all experienced health care experts. We, at LAM Pharmaceutical,
Corp., feel confident and enthusiastic about this opportunity to work with them."
Joseph Slechta, President & COO of LAM Pharmaceutical, Corp. added, "LAM management believes that our alliance with RxCentric
represents a pivotal part of our overall marketing program for LAM IPM(TM) Wound Gel."
About RxCentric
RxCentric Inc. (www.rxcentric.com) is the pioneer of technology-enabled sales and marketing solutions for the life sciences
industry providing customized and targeted online product marketing capability that extends the reach and frequency of existing offline
marketing and sales activities. RxCentric Inc. is a privately held company with locations in New York, Morristown NJ, Philadelphia and
Orange County, CA.
www.newsalert.com/bin/...bb&Nav=na-search-&StoryTitle=otc%20bb
Hier deutet sich ein neuer Highflyer an: Die Umsätze stimmen auch - einsteigen, bevor es zu spät sein wird.
MfG
Star Ikone ;)
LEWISTON, N.Y., March 27 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt
Stock Exchange: LAM), www.lampharm.com announced today that its breakthrough wound care product -- LAM
IPM(TM) Wound Gel -- will be eligible for the Medicare Homecare Reimbursement Plan once it receives FDA approval and is
recommended for use in patients who are being treated by wound care nurses under the cognizance of qualified wound care
professionals.
This highly successful, and fast expanding part of the Medicare system, provides for many patients to be treated at home, instead
of in a much more expensive hospital setting.
LAM IPM(TM) Wound Gel is classified as a hydrogel 510(k) device (FDA Assigned No. K020325) and, as such, home
treatment by specialized wound care nurses is currently paid for by the Medicare system, for this class of product, following
approval by the FDA. Monitoring of individual cases and progress reports are required by medical officials.
Because most patients suffering from severe skin ulcers, including diabetic ulcers, venous stasis ulcers and other severe ulcerated
skin conditions are over the age of 65, and thus are covered by Medicare, LAM Pharmaceutical, Corp. expects to be a major
beneficiary of this highly successful and enlightened Medicare program.
LAM IPM(TM) Wound Gel has enjoyed an 88% success rate in creating an effective moist environment to assist healing in
hard-to-heal ulcers in both animal and human studies while maintaining an extremely low incidence of side effects.
Alan Drizen, C.E.O. of LAM Pharmaceutical, Corp., said, ``We expect a decision from FDA on or about April 30, 2002,
regarding our 510(k) application. Upon receipt of a positive response, management believes that our forecast of US $27 million in
sales for 2003 and US $50 million in sales for 2004 can now be considered conservative. The suitability of our wound care
hydrogel (LAM IPM(TM) Wound Gel) for homecare, under present Medicare guidelines, makes it ideal for homecare use.``
Dazu die guten News vom 12.3.:
March 12, 2002 07:00
LAM Pharmaceutical Corp. Signs Marketing Agreement with RxCentric Inc. of New York City
Jump to first matched term
LEWISTON, N.Y., March 12 /PRNewswire-FirstCall/ -- LAM Pharmaceutical Corp. (OTC Bulletin Board: LAMP; Frankfurt Stock Exchange:
LAM), www.lampharm.com, is pleased to announce that it has signed a marketing agreement with RxCentric Inc. of New York City
in connection with its anticipated launch of its breakthrough product for the management of severe skin ulcers, LAM IPMTM Wound Gel.
RxCentric Inc., a leading provider of technology-enabled sales and marketing solutions for the pharmaceutical and biotech industry, has
captured the attention of the pharmaceutical and biotechnology and the medical community in the last few years by way of its novel and
innovative approach to marketing and product dissemination to medical professionals.
Using its database access to several hundred thousand of the busiest, office based, prescribing medical professionals, RxCentric Inc.
has developed 4-6 minute medical information messages which it uses to target the various types of health care professionals with
important information on new and existing products.
"Our agreement with LAM is a prime example of how we can customize online solutions quickly and at reasonable cost to help
pharmaceutical companies keep products top-of-mind with physicians," said Richard Findlay, President and Chief Executive Officer of
RxCentric. "The pharmaceutical industry rapidly is discovering that the Internet can improve and strengthen relationships with its key
customers -- physicians -- and extend the reach of sales programs. RxCentric`s services can support large and small products at all
stages of the product lifecycle: pre-launch, launch, mature, and late life-cycle."
RxCentric Inc. has designed successful programs for a significant number of major multi-national companies and has accepted LAM
Pharmaceutical, Corp. as a client because it strongly believes LAM IPM(TM) Wound Gel will become a leader in the ulcer sector of the
wound care market, which is the fastest growing segment of the pharmaceutical industry.
Alan Drizen, CEO of LAM Pharmaceutical, Corp. said, "This agreement comes at a perfect time for us. Our anticipated launch of our first,
and possibly most major product, is approximately only two months away. The national exposure that RxCentric Inc. will give LAM
IPM(TM) Wound Gel coupled with the medical presentation to the 15th Annual Symposium on Advanced Wound Care in Baltimore,
Maryland, coming at the end of April, will give many of our target group of health care professionals the information and samples they
need to learn about and evaluate the product in the most timely way."
Alan Drizen continued, "RxCentric executives and top management are all experienced health care experts. We, at LAM Pharmaceutical,
Corp., feel confident and enthusiastic about this opportunity to work with them."
Joseph Slechta, President & COO of LAM Pharmaceutical, Corp. added, "LAM management believes that our alliance with RxCentric
represents a pivotal part of our overall marketing program for LAM IPM(TM) Wound Gel."
About RxCentric
RxCentric Inc. (www.rxcentric.com) is the pioneer of technology-enabled sales and marketing solutions for the life sciences
industry providing customized and targeted online product marketing capability that extends the reach and frequency of existing offline
marketing and sales activities. RxCentric Inc. is a privately held company with locations in New York, Morristown NJ, Philadelphia and
Orange County, CA.
www.newsalert.com/bin/...bb&Nav=na-search-&StoryTitle=otc%20bb
Hier deutet sich ein neuer Highflyer an: Die Umsätze stimmen auch - einsteigen, bevor es zu spät sein wird.
MfG
Star Ikone ;)
